Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Saturday, June 20, 2020
Fighting the Coronavirus
Eli Lillyand Co. (LLY), with its $135 billion market cap, is an American pharmaceutical company that recently said it could have a drug specifically designed to treat COVID-19 as early as September of this year if all goes well with the two antibody therapies it is testing. That's only three short months away.
The drugs it is testing are a type of antibody-drug called monoclonal antibodies. Simply put, they are molecules that are engineered to attach to defects in cells and mimic the antibodies the body already produced as part of our immune response.
The advantage of this type of drug and why they believe they can get a vaccine out so fast is that this type of biotech medicine is currently being used to treat diseases and conditions such as cancer and arthritis. According to Eli Lilly's Chief Scientific Officer Daniel Sokvronsky, this type of drug is more likely to be effective than repurposing a current drug to fight against the virus.
Right now, Eli Lilly has initiated patient testing for two separate antibody treatments along with a third that could work alongside the other two.
If everything works out, it has the capacity to make hundreds of thousands of doses by the end of the year. While the better solution is to widely inoculate people with a vaccine when available, this could help people who have the disease or who were recently exposed.
It could also help aging or sick people like nursing home patients, where vaccines tend to not work as well.
Johnson & Johnson(JNJ) is another large pharmaceutical company that is also developing a vaccine. JNJ began production of its trial COVID-19 vaccine in April and has set a high bar for themselves in getting through its trials quickly.
As one of the five vaccine programs that have been designated by the Trump administration to be the most likely to produce a working COVID-19 vaccine, there could be a lot of promise here.
The company recently announced that it is accelerating its vaccine candidate with its Phase 1/2a clinical trial to begin in the second half of July, which was initially scheduled to begin in September.
According to Paul Stoffels, J&J's Chief Scientific Officer, "based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine." On top of that, the company is already in discussions with the National Institutes of Allergy and Infectious Diseases to start Phase 3 trials early. While this may be planning far ahead, it is nice to see regulatory agencies understand the need to get a vaccine out as soon as possible and help accelerate programs that might be successful in treating COVID-19
As J&J progresses its clinical development, it is also increasing its manufacturing capacity. Assuming the vaccine is safe and effective, they are committed to the go
Yes, but why isn't this mornings RNS showing?
I think it's the tip of the iceberg!
No, I understand. Thanks.
stix40. I am with HL also....was sent a share certificate a few weeks ago.
No problem, just confirmes I made the right judgement...not easy on AIM .
Well said...thank god for your knowledge!
Agree...hope he continues posting!
Shell! Say no more!!
Lol...good one!
It's always been on the cards....but when?
Forget all the rhetoric, if a deal is made this will take off!
will take all my shares at 70.45p
Want all my shares!
I think it will be shockingly excellent!
All going to plan as far as i'm concerned...we will find out soon enough..stay chilled!
is going to be massive...and some of us are lucky enough to be in it!